Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01570192 · ClinicalTrials.gov registry record · Phase 2
Clinical Trials to Reduce the Risk of Antimicrobial Resistance
A Phase 2 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT01570192 is a Phase 2 study that was terminated before completion, run by University of Florida. The registered enrollment target is 43 participants.
The verdict
NCT01570192, a Phase 2 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate a low rate of emergence of antibiotic resistance in P. aeruginosa and Acinetobacter spp during the treatment of hospitalized patients with pneumonia requiring mechanical ventilation treated with PD optimized meropenem administered as a prolonged infusion in combination with a parenteral aminoglycoside plus tobramycin by inhalation (Group 1) compared to therapy with meropenem alone (Group 2 - control arm).
Interventions
- DRUG IV meropenem
- DRUG I.V. Meropenem
- DRUG Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h
- DRUG Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.
- DEVICE tobramycin nebulization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-09 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01570192
The ClinicalTrials.gov registry entry for NCT01570192 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which IV meropenem is the first listed.
NCT01570192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01570192 about?
NCT01570192 is a clinical study titled "Clinical Trials to Reduce the Risk of Antimicrobial Resistance". The primary objective of this study is to demonstrate a low rate of emergence of antibiotic resistance in P. aeruginosa and Acinetobacter spp during the treatment of hospitalized patients with pneumonia requiring mechanical ventilation treated with PD optimized meropenem administered as a prolonged ...
What is the current status of trial NCT01570192?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2010-09. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01570192?
The interventions under investigation include: IV meropenem (DRUG), I.V. Meropenem (DRUG), Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h (DRUG), Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage. (DRUG), tobramycin nebulization (DEVICE).
Who is sponsoring clinical trial NCT01570192?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.